Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a clinical-stage biotech developing genomic medicines, with zero direct political spending, zero federal contracts, and zero insider buys, but faces moderate legislative exposure from 8 healthcare bills with estimated revenue impacts up to $5.13M each.
BusinessWhat SGMO does
Sangamo Therapeutics is a clinical-stage biotechnology company focused on developing genomic medicines using zinc finger protein technology. Its revenue is primarily from collaborations and licenses, with no commercial products; it relies on equity financing and partnership milestones. The company operates in gene therapy and cell therapy for rare diseases and neurology.
Lifetime Government AwardsSGMO federal contracts
SGMO doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding SGMO
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting SGMOLive legislation impacting this stock
Political ProfileWhere SGMO sits in Washington
[object Object]
STRUCTURAL: Zero lobbying spend, zero donations, zero federal contracts. EVIDENTIARY: Zero insider buys in 180 days, zero congressional trades. Net: No direct political engagement, but legislative exposure from healthcare bills provides moderate regulatory risk/opportunity.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
High regulatory density from healthcare bills affecting revenueFDA, CMS"Recent bill_impacts shows 8 bills with impact_ratios 0.0341-0.0359, estimated revenue impacts $4.87M-$5.13M each"
Regulatory opportunities
-
Potential favorable legislation for genomic medicinesCongress"Recent bill_impacts includes multiple healthcare bills with positive estimated revenue impact, though specific carveouts absent"
Live signals + predictions for SGMO — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades SGMO
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord